Medidata Solutions, Inc.
07/21/15

Medidata Reports Record Second Quarter 2015 Revenues

NEW YORK--(BUSINESS WIRE)-- Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced its financial results for the second quarter of 2015 and reiterated its revenue and profitability guidance.

"Our strong results this quarter and year to date highlight our ability to capitalize on the growing opportunities in our space and reflect great execution by the Medidata team," said Tarek Sherif, Medidata's chairman and chief executive officer. "Record sales, growing customer adoption and profitability are being driven by innovative new and established life sciences companies turning to our cloud-based platform and data analytics to optimize their clinical development programs. Medidata is helping its clients to navigate the shift to the cloud, allowing the drug development industry to capitalize on a period of unprecedented innovation in science, connectivity and deep data, and helping speed life-enhancing drugs to market for the patients who need them."

Second Quarter 2015 Results

Additional Highlights

"Our strong business performance in the first half of the year positions us well to achieve our full-year objectives," said Rouven Bergmann, Medidata's chief financial officer. "We expect increased profitability, operating margin expansion and strong cash flows in 2015. Going forward, we will continue to invest strategically to help our growing customer base move their mission-critical development efforts into the cloud while simultaneously driving Medidata's long-term sustainable growth."

Financial Outlook

For the full-year 2015, the Company expects the following:

*The current estimated GAAP equivalents to our non-GAAP guidance reflect the impact of approximately $5.0 million on a pre-tax basis of additional stock-based compensation expense relative to our prior outlook.

Conference Call

The Company plans to host its investor conference call today at 8:00 a.m. Eastern time. The investor conference call will be available via live webcast on the "Investor" section of Medidata's website at http://investor.mdsol.com. To participate by telephone, domestic participants may dial 877-303-2528 and international participants may dial 847-829-0023. Those interested in participating in the conference call should dial in at least 10 minutes prior to the call to register. Participants can also join the call via a simultaneous live audio webcast, which will be made available on the "Investor" section of Medidata's website at http://investor.mdsol.com. A replay of the conference call can be accessed until Tuesday, August 4, 2015, by dialing 800-585-8367 domestically or 404-537-3406 internationally, with the passcode 80354484. An archive of the call will also be hosted on the "Investor" section of Medidata's website, http://investor.mdsol.com, for a limited period of time.

About Medidata

Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud® brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

Cautionary Statement

Certain statements made in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about Medidata Solutions, Inc. ("Medidata"), including but not limited to statements about Medidata's forecast of financial performance, products and services, business model, strategy and growth opportunities, and competitive position. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements. In particular, the risks and uncertainties include, among other things, risks associated with possible fluctuations in our financial and operating results; errors, interruptions or delays in our service or our web hosting; the financial impact of any future acquisitions; our ability to continue to release, and gain customer acceptance of, new and improved versions of our products; changes in our sales and implementation cycles; competition; our ability to retain and expand our customer base or increase new business from those customers; our ability to hire, retain and motivate our employees and manage our growth; regulatory developments; litigation; and general developments in the economy. For additional disclosure regarding these and other risks faced by the company, see disclosures contained in Medidata's public filings with the Securities and Exchange Commission, including the "Risk Factors" section of Medidata's Annual Report on Form 10-K for the year ended December 31, 2014. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof, and Medidata undertakes no obligation to update such statements as a result of new information.

(1) Non-GAAP Financial Information

Medidata provides non-GAAP operating income, net income and net income per share applicable to common stockholders data as additional information for its operating results. These measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. Non-GAAP operating income excludes the impact of depreciation, amortization of intangible assets associated with acquisitions, and stock-based compensation expense. Adjusted non-GAAP net income excludes the impact of tax-affected amortization of intangible assets associated with acquisitions, stock-based compensation expense, and non-cash interest expense on convertible senior notes. Management uses these non-GAAP measures to evaluate its financial results, develop budgets, manage expenditures, and as an important factor in determining variable compensation. In addition, investors frequently have requested information from management regarding depreciation, amortization and other non-cash charges, such as share-based compensation, and management believes, based on discussions with investors, that these non-GAAP measures enhance investors' ability to assess Medidata's historical and projected future financial performance. While management believes these non-GAAP financial measures provide useful supplemental information to investors, there are limitations associated with the use of non-GAAP financial measures. One limitation of non-GAAP operating income is that it excludes depreciation and amortization, which represents the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in our business. Medidata compensates for these limitations by using these non-GAAP financial measures as supplements to GAAP financial measures and by reviewing the reconciliations of the non-GAAP financial measures to their most comparable GAAP financial measures. Investors are encouraged to review the reconciliations of these non-GAAP financial measures to the comparable GAAP results, which are attached to this press release.

(2) Adjusted subscription backlog equals subscription backlog plus outstanding intra-year renewals.

 
MEDIDATA SOLUTIONS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
(Amounts in thousands, except per share data)
      Three Months Ended
June 30,
  Six Months Ended
June 30,
2015   2014   2015   2014
Revenues

Subscription

$ 83,929 $ 68,947 $ 162,678 $ 132,758
Professional services 14,155   14,276   27,846   27,105  
Total revenues 98,084 83,223 190,524 159,863
Cost of revenues (1)(2)
Subscription 12,354 11,221 23,827 22,307
Professional services 10,557   9,753   21,260   19,466  
Total cost of revenues 22,911 20,974 45,087 41,773
Gross profit 75,173 62,249 145,437 118,090
Operating costs and expenses
Research and development (1) 22,519 17,311 44,430 35,100
Sales and marketing (1)(2) 25,724 20,425 50,042 41,157
General and administrative (1) 21,943   17,373   42,512   34,419  
Total operating costs and expenses 70,186   55,109   136,984   110,676  
Operating income 4,987 7,140 8,453 7,414
Interest and other income (expense)
Interest expense (3,997 ) (3,827 ) (7,955 ) (7,608 )
Interest income 612 420 1,146 815
Other (expense) income, net (34 ) (28 ) (68 ) 6  
Total interest and other expense, net (3,419 ) (3,435 ) (6,877 ) (6,787 )
Income before income taxes 1,568 3,705 1,576 627
Provision for income taxes 55   1,409   (94 ) 146  
Net income $ 1,513   $ 2,296   $ 1,670   $ 481  
Earnings per share
Basic $ 0.03   $ 0.04   $ 0.03   $ 0.01  
Diluted $ 0.03   $ 0.04   $ 0.03   $ 0.01  
Weighted average common shares outstanding
Basic 53,647 52,457 53,453 52,284
Diluted 56,191 54,828 56,050 54,998
(1) Stock-based compensation expense included in cost of revenues and operating costs and expenses is as follows:
Cost of revenues $ 1,311 $ 1,027 $ 2,559 $ 2,099
Research and development 2,013 817 3,799 1,729
Sales and marketing 2,460 1,060 4,827 3,411
General and administrative 8,352   5,726   14,621   11,090  
Total stock-based compensation   $ 14,136   $ 8,630   $ 25,806   $ 18,329  
(2) Amortization of intangible assets included in costs of revenues and operating costs and expenses is as follows:
Cost of revenues $ 180 $ 111 $ 359 $ 219
Sales and marketing 30   30   59   60  
Total amortization of intangible assets   $ 210   $ 141   $ 418   $ 279  
 

 
MEDIDATA SOLUTIONS, INC.

Reconciliation of GAAP Operating Income and GAAP Net Income to
Non-GAAP Operating Income and Adjusted Non-GAAP Net Income (Unaudited)

(Amounts in thousands, except per share data)
     

Three Months Ended
June 30,

 

Six Months Ended
June 30,

2015   2014   2015   2014
Operating income:  
GAAP operating income $ 4,987 $ 7,140 $ 8,453 $ 7,414
GAAP operating margins 5.1 % 8.6 % 4.4 % 4.6 %
Stock-based compensation 14,136 8,630 25,806 18,329
Depreciation and amortization 2,637   2,609   5,190     5,144  
Non-GAAP operating income $ 21,760   $ 18,379   $ 39,449     $ 30,887  
Non-GAAP operating margins 22.2 % 22.1 % 20.7 %   19.3 %
Net income:
GAAP net income $ 1,513 $ 2,296 $ 1,670 $ 481
Stock-based compensation 14,136 8,630 25,806 18,329
Amortization 210 141 418 279
Non-cash interest expense on convertible senior notes (1) 3,273 3,102 6,501 6,162
Tax impact on add-back items (2) (7,048 ) (4,749 ) (13,090 )   (9,908 )
Adjusted non-GAAP net income $ 12,084   $ 9,420   $ 21,305     $ 15,343  
GAAP basic earnings per share $ 0.03   $ 0.04   $ 0.03     $ 0.01  
GAAP diluted earnings per share $ 0.03   $ 0.04   $ 0.03     $ 0.01  
Adjusted Non-GAAP basic earnings per share $ 0.23   $ 0.18   $ 0.40     $ 0.29  
Adjusted Non-GAAP diluted earnings per share $ 0.22   $ 0.17   $ 0.38     $ 0.28  

(1) Amount represents non-cash interest expense, including amortization of debt discount and issuance costs, on our 1.00% convertible senior notes issued during the third quarter of 2013. We exclude this incremental non-cash interest expense for purposes of calculating adjusted non-GAAP net income. We believe that excluding these expenses from our non-GAAP measures is useful to investors because such incremental non-cash interest expense does not generate a cash outflow for the company and the debt issuance costs do not represent a cash outflow for the company except in the period the notes were issued; therefore both are not indicative of our continuing operations.

(2) Tax impact calculated using a 40% tax rate.

The table above presents a reconciliation of GAAP to non-GAAP operating income, net income, and net income per share applicable to common stockholders for the three and six months ended June 30, 2015 and 2014. Non-GAAP operating income excludes the impact of depreciation, amortization of intangible assets associated with acquisitions, and stock-based compensation expense. Adjusted non-GAAP net income excludes the impact of tax affected amortization of intangible assets associated with acquisitions, stock-based compensation expense, and non-cash interest expense on convertible senior notes.

 
MEDIDATA SOLUTIONS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
(Amounts in thousands, except per share data)
    June 30, 2015   December 31, 2014
ASSETS
Current assets:
Cash and cash equivalents $ 43,366 $ 39,517
Marketable securities 222,625 233,284
Accounts receivable, net of allowance for doubtful accounts of $1,945 and $1,517, respectively 93,507 68,475
Prepaid commission expense 2,232 2,819
Prepaid expenses and other current assets 15,701 13,661
Deferred income taxes 4,158   96  
Total current assets 381,589 357,852
Restricted cash 5,582 5,118
Furniture, fixtures and equipment, net 42,491 38,579
Marketable securities, long-term 206,426 183,842
Goodwill 19,083 19,025
Intangible assets, net 1,394 1,816
Deferred income taxes, long-term 8,004 8,066
Other assets 7,756   7,919  
Total assets $ 672,325   $ 622,217  
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 2,766 $ 3,738
Accrued payroll and other compensation 15,430 15,574
Accrued expenses and other 16,086 12,638
Deferred revenue 80,583   62,890  
Total current liabilities 114,865   94,840  
Noncurrent liabilities:
1.00% convertible senior notes, net 246,748 240,886
Deferred revenue, less current portion 933 1,374
Deferred tax liabilities 232 238
Other long-term liabilities 21,069   20,180  
Total noncurrent liabilities 268,982   262,678  
Total liabilities 383,847   357,518  
Commitments and contingencies
Stockholders' equity:
Preferred stock, par value $0.01 per share; 5,000 shares authorized, none issued and outstanding

Common stock, par value $0.01 per share; 200,000 shares authorized; 57,567 and 56,301 shares
issued; 55,285 and 54,413 shares outstanding, respectively

576 563
Additional paid-in capital 339,408 301,465
Treasury stock, 2,282 and 1,888 shares, respectively (61,204 ) (45,049 )
Accumulated other comprehensive loss (1,604 ) (1,912 )
Retained earnings 11,302   9,632  
Total stockholders' equity 288,478   264,699  
Total liabilities and stockholders' equity $ 672,325   $ 622,217  
 

 
MEDIDATA SOLUTIONS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
(Amounts in thousands)
     

Six Months Ended
June 30,

2015   2014
Cash flows from operating activities
Net income $ 1,670 $ 481
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 5,190 5,144
Stock-based compensation 25,806 18,329
Amortization of discounts or premiums on marketable securities 2,502 2,714
Deferred income taxes (5,846 ) (3,146 )
Amortization of debt issuance costs 639 639
Amortization of debt discount 5,862 5,523
Excess tax benefit associated with equity awards (3,712 ) (2,648 )
Provision for doubtful accounts 550 266
Changes in operating assets and liabilities:
Accounts receivable (33,894 ) (18,328 )
Prepaid commission expense (123 ) 657
Prepaid expenses and other current assets (3,303 ) 1,018
Other assets 1,497 87
Accounts payable (702 ) 2,476
Accrued payroll and other compensation 196 (7,134 )
Accrued expenses and other 4,439 5,437
Deferred revenue 27,085 3,588
Other long-term liabilities 889   2,711  
Net cash provided by operating activities 28,745   17,814  
Cash flows from investing activities
Purchase of furniture, fixtures and equipment (5,925 ) (11,602 )
Purchase of available-for-sale securities (140,856 ) (113,019 )
Proceeds from sale of available-for-sale securities 126,632 141,214
Net (increase) decrease in restricted cash (464 ) 226  
Net cash (used in) provided by investing activities (20,613 ) 16,819  
Cash flows from financing activities
Proceeds from exercise of stock options 5,199 1,885
Proceeds from employee stock purchase plan 2,960 2,513
Excess tax benefit associated with equity awards 3,712 2,648
Payment of acquisition-related earn-out (704 )
Repayment of obligations under capital leases (17 ) (39 )
Acquisition of treasury stock (16,154 ) (28,058 )
Repayment of notes payable   (85 )
Net cash used in financing activities (4,300 ) (21,840 )
Effect of exchange rate changes on cash and cash equivalents 17   71  
Net increase in cash and cash equivalents 3,849 12,864
Cash and cash equivalents - Beginning of period 39,517   22,328  
Cash and cash equivalents - End of period $ 43,366   $ 35,192  
 

Medidata Solutions
Investors:
Hulus Alpay, 212-419-1025
halpay@mdsol.com
or
Media:
Nicole Pariser, 212-659-1069
npariser@mdsol.com

Source: Medidata Solutions

News Provided by Acquire Media